A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
Phase 2
Terminated
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- Drug: SHR-1701、 BP102 、XELOXDrug: placebo、 BP102、 XELOX
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT04856787
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 548
- Registration Number
- NCT04840485
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath